INS and Alzheimer disease: In addition, patients with Alzheimer’s disease have abnormal insulin metabolism associated with the apolipoprotein E,33 corroborated by reports of reduced hippocampal insulin-degrading enzyme (an amyloid-β-degrading metalloprotease) in APOE-ε4 carriers.34